Actinium Pharmaceuticals (ATNM) vs. The Competition Financial Survey

Actinium Pharmaceuticals (NYSE:ATNM) is one of 1,025 public companies in the “Pharmaceutical preparations” industry, but how does it compare to its competitors? We will compare Actinium Pharmaceuticals to related companies based on the strength of its risk, institutional ownership, valuation, earnings, dividends, analyst recommendations and profitability.

Analyst Ratings

This is a breakdown of current recommendations for Actinium Pharmaceuticals and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0	1	4	0	2.80
Actinium Pharmaceuticals Competitors	7245	20196	47120	1112	2.56

Actinium Pharmaceuticals presently has a consensus target price of $11.40, indicating a potential upside of 540.45%. As a group, “Pharmaceutical preparations” companies have a potential upside of 63.67%. Given Actinium Pharmaceuticals’ stronger consensus rating and higher possible upside, research analysts plainly believe Actinium Pharmaceuticals is more favorable than its competitors.

Earnings & Valuation

This table compares Actinium Pharmaceuticals and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Actinium Pharmaceuticals	$81,000.00	-$48.82 million	-1.04
Actinium Pharmaceuticals Competitors	$9.45 billion	$147.48 million	-4.46

Actinium Pharmaceuticals’ competitors have higher revenue and earnings than Actinium Pharmaceuticals. Actinium Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

Actinium Pharmaceuticals has a beta of 0.14, suggesting that its share price is 86% less volatile than the S&P 500. Comparatively, Actinium Pharmaceuticals’ competitors have a beta of 0.86, suggesting that their average share price is 14% less volatile than the S&P 500.

Insider and Institutional Ownership

27.5% of Actinium Pharmaceuticals shares are held by institutional investors. Comparatively, 44.7% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 4.0% of Actinium Pharmaceuticals shares are held by company insiders. Comparatively, 14.0% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Actinium Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-101.69%	-48.91%
Actinium Pharmaceuticals Competitors	-3,628.10%	-299.05%	-32.34%

Summary

Actinium Pharmaceuticals competitors beat Actinium Pharmaceuticals on 7 of the 13 factors compared.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company’s research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.